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Asthma inception is associated with respiratory viral infection, especially infection with
respiratory syncytial virus (RSV) and/or human rhinovirus (HRV), in the vast majority of
cases. However, the reason why RSV and HRV induce the majority of bronchiolitis cases
during early childhood and why only a small percentage of children with RSV- and HRV-
induced bronchiolitis later develop asthma remains unclear. A genetic association study has
revealed the important interaction between viral illness and genetic variants in patientswith
asthma. Severe RSV- and HRV-induced bronchiolitis may be associated with a deﬁciency
in the innate immune response to RSV and HRV. RSV and HRV infections in infants with
deﬁcient innate immune response and the dysfunction of regulatoryT cells are considered
to be a risk factor for the development of asthma. Sensitization to aeroallergens, beginning
in the ﬁrst year of life, consistently predisposes children toHRV-inducedwheezing illnesses,
but the converse is not true. Some evidence of virus speciﬁcity exists, in that allergic
sensitization speciﬁcally increased the risk of wheezing in individuals infected with HRV,
but not RSV. Administration of Palivizumab, a humanized monoclonal antibody that targets
the A antigenic site of the Fusion-protein of RSV, decreases the risk of hospitalization in
high-risk infants and the risk of recurrent of wheezing. However, palivizumab did not have
any effect on subsequent recurrent wheezing in children with a family history of atopy.
These ﬁndings suggest that infection with RSV and infection with HRV might predispose
individuals to recurrent wheezing through an atopy-independent and an atopy-dependent
mechanism, respectively. Respiratory virus-induced wheezing illnesses may encompass
multiple sub-phenotypes that relate to asthma in different ways.
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INTRODUCTION
Infection with respiratory syncytial virus (RSV) and/or human
rhinovirus (HRV) is the most important cause of lower respira-
tory tract disease in infants and young children (Heilman, 1990)
and is themajor cause of bronchiolitis in infants (Henderson et al.,
1979; Rakes et al., 1999). RSV- and/or HRV-induced bronchioli-
tis during early childhood is strongly linked to the subsequent
development of allergies and asthma (Sigurs et al., 2000; Schauer
et al., 2002; Lemanske et al., 2005; Kusel et al., 2007; Jackson et al.,
2008, 2013; Sly et al., 2008; Stern et al., 2008). However, the rea-
sons why RSV and HRV induce the majority of bronchiolitis cases
during early childhood and why only a small percentage of chil-
dren with RSV- and/or HRV-induced bronchiolitis later develop
atopy or asthma remain unclear. Accumulating evidence suggests
that both genetic and environmental factors determine the type
of immune response to infection with RSV and/or HRV and that
the type of immune response may, in turn, affect the development
of asthma (Martinez, 2003; Caliskan et al., 2013). This chapter
focuses on the immunological mechanisms that may explain why
asthma inception is associated with RSV- and HRV-infection.
INTERACTION BETWEEN VIRAL ILLNESS AND GENETIC
VARIANTS IN PATIENTS WITH ASTHMA
Asthma inception and exacerbation are associated with respira-
tory viral infection in the vast majority of cases (Kusel et al., 2007;
Jackson et al., 2008; Sly et al., 2008; Stern et al., 2008). Severe
bronchitis following infectionwithRSV can occur in a small subset
of infected infants (Sly et al., 2008). Viral infections of the lower
respiratory tract are likely to result in wheezing if they induce
inﬂammation and edema of the airway epithelium, decreasing the
airway diameter (Sly et al., 2008). The frequency of lower res-
piratory viral infection accompanied by wheezing inﬂuences the
risk of asthma inception (Sly et al., 2008). A genetic association
study involving 470 children hospitalized for RSV-induced bron-
chiolitis, their parents, and 1008 randomly selected population
controls showed that single-nucleotide polymorphisms (SNPs) of
VDR (vitamin D receptor), JUN, IFNA5, NOS2A, and FCER1A
were signiﬁcantly associated with severe RSV-induced bronchi-
olitis at both the allele and genotype levels (Janssen et al., 2007).
Genetic polymorphisms of SFTPA (surfactant protein A), SFTPD
(surfactant protein D), TLR (toll like receptor) 4, TNF (tumor
necrosis factor), IL4 (interleukin 4), IL9, IL10, IL8, IL13, IL4RA,
and CCL5 have been reportedly associated with a susceptibility to
RSV-induced bronchiolitis (Huckabee and Peebles, 2009). Very
recently, a signiﬁcant interaction between the 17q21 genotype
and human RSV-induced wheezing illness was demonstrated in
two birth cohorts of children: the childhood origins of asthma
(COAST), and the Copenhagen Prospective Study on Asthma in
Childhood (COPSAC; Caliskan et al., 2013). The effects of 17q21
variants on an increased susceptibility to asthma are restricted
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to patients with a history of HRV-induced wheezing illness dur-
ing early life (Caliskan et al., 2013). These studies emphasize the
important interaction between virus-induced illness and genetic
variants in patients with asthma.
CELLULAR IMMUNITY OF VIRUS-INDUCED ASTHMA
(1) Is RSV- and/or HRV-induced severe bronchiolitis in children
associated with a T helper type 2 (Th2)-predominant immune
response?
RSV-induced severe bronchiolitis in children is associated
with a Th2-predominant immune response (Renzi et al., 1997;
Roman et al., 1997; Bendelja et al., 2000; Pala et al., 2002; van
der Sande et al., 2002; Joshi et al., 2003; Legge and Braciale,
2003) or a decreased Th1 immune response (Joshi et al., 2003;
Legge andBraciale, 2003). The concentration of Th2 cytokines was
higher than that of interferon (IFN)-γ in nasopharyngeal secre-
tions (NSP; Bermejo-Martin et al., 2007), particularly in infants
less than threemonths old (Kristjansson et al., 2005). On the other
hand, undetectable or very low Th2 cytokine concentrations have
also been reported (Bont et al., 2001; Garofalo et al., 2001; Bennett
et al., 2007; Garcia et al., 2012).
The majority of virus-infected mouse studies have been per-
formed using RSV because the major group of HRV (88%
of known HRV serotypes) uses human intercellular adhesion
molecule-1 (ICAM-1) as a cellular receptor and cannot bind to
mouse ICAM-1. Regarding HRV-induced asthma mouse models,
three novel mouse models of HRV infection have been recently
developed: infection with a minor-group HRV (the receptor is the
low-density lipoprotein receptor family) in BALB/c mice, infec-
tion with a major-group HRV in transgenic BALB/c expressing a
mouse-human ICAM-1 chimera, and HRV-induced exacerbation
of allergic airway inﬂammation (Bartlett et al., 2008). These mod-
els are likely to be useful for the future development of therapies
for asthma exacerbation.
In the majority of RSV-infected mouse studies, the induction
of Th2 cytokines (including IL-4 and IL-5) is not observed in
bronchial alveolar lavage (BAL) ﬂuid or the lung tissues of RSV-
infected mice (Peebles et al., 2001; Chavez-Bueno et al., 2005; Lee
et al., 2008). A comparison of mouse strains showed that BALB/c
and DBA/2mice had a signiﬁcantly higher airway hyper-reactivity
over almost the entire time course up to 20 days after RSV
exposure, compared with C57BL/6 mice (Tekkanat et al., 2001).
However, even the BALB/c mice required a very high intranasal or
intratracheal inoculum (105 or 106 PFUs) to elicit airway hyper-
responsiveness (AHR; Tekkanat et al., 2001; Wang et al., 2004).
Therefore, both the mouse strains and the amounts of virus that
were used should be taken into consideration when comparing
different mouse experiments.
(2) Is severe RSV- and/or HRV-induced bronchiolitis associ-
ated with deﬁcient IFN production?
The concentrations of IFN-γ in samples of bloodmononuclear
cells or nasopharyngeal aspirates from RSV- and/or HRV-infected
infants were inversely correlatedwith disease severity (Aberle et al.,
1999; Bont et al., 1999, 2001; Renzi et al., 1999; Legg et al., 2003;
Bennett et al., 2007; Garcia et al., 2012). These clinical studies sug-
gest that IFN-γ plays an important role in determining the severity
of RSV- and/or HRV-induced bronchiolitis.
STAT1-knockout (STAT1−/−) BALB/c mice, which are inca-
pable of responding to type II IFN (IFN-γ) or to type I IFN (IFN-α
and β), showed markedly increased levels of inﬂammation, com-
pared with wild-type (WT) mice, after infection with RSV, despite
similar virus titers in the lung and similar rates of viral clearance
(Durbin et al., 2002). STAT1−/− mice, but notWT or IFN-γ−/−-
infected mice, exhibited eosinophilic and neutrophilic pulmonary
inﬁltrates. Although IFN-γ had been induced in infected lung tis-
sues from both STAT1−/− and WT mice, preferential IL-4, IL-5,
and IL-13 induction was only seen in the STAT1−/− mice. These
ﬁndings suggest that both type I and type II IFNs play impor-
tant roles in the Th1 antigen-speciﬁc immune response to RSV
infection (Durbin et al., 2002).
(3) Is infection with RSV and/or HRV during infancy a
risk factor for the development of asthma and possible allergic
sensitization?
Among the viral wheezing illnesses that occur in outpa-
tients during infancy and early childhood, those caused by HRV
infections are the most signiﬁcant predictors of the subsequent
development of asthma at an age of 6 years, with an odds ratio
(OR) of 9.8 for a high-risk birth cohort (Jackson et al., 2008).
From birth to 3 years of age, wheezing accompanied by RSV infec-
tion alone was associated with an increased asthma risk at an age
of 6 years, with an OR of 2.6 (Jackson et al., 2008). Two important
observationsmust be considered. First,most severe RSV infections
occur between the 8th and 24th postnatal week. 80% of infants
experience anHRV infection by the age of 1 year. Second, repeated
infection is common at all ages, indicating the possibility of impor-
tant interactions and outcomes in RSV- and/or HRV-re-infected
hosts.
Culley et al. (2002) compared the consequences of re-infection
with RSV between neonatal mice (during the 1 week of life) and
weanling mice (at 3 weeks of age) that had been initially infected
with RSV. The primary infection of neonatal BALB/c mice with
RSV was associated with a reduced and delayed IFN-γ response
(Culley et al., 2002). Upon re-infection with RSV, a severer weight
loss with the increased inﬂammatory cell recruitment of Th2 cells
and eosinophils was induced in the neonatal mice, compared
with the weanling mice that had been initially infected with RSV
(Culley et al., 2002). These results show the crucial importance of
age at the time of the ﬁrst infection in determining the outcome
of re-infection and suggest that the environment of the neonatal
lung is a major determinant of cytokine production and disease
patterns in later life. Neonatal RSV infection is thought to lead
to a predisposition to the development of airway eosinophilia
and enhanced AHR via an IL-13-dependent mechanism during
re-infection, whereas infection at a later age protects against the
development of these altered airway responses after re-infection
(Dakhama et al., 2005).
Severe RSV bronchiolitis has been associated with deﬁcient
IFN-γ production in humans (Bont et al., 2001; Bennett et al.,
2007; Garcia et al., 2012), but the role of this cytokine in deter-
mining the outcome of re-infection is unknown. To deﬁne the
role of IFN-γ in the development of RSV-induced AHR and lung
histopathology in mice, WT and IFN-γ−/− mice were infected
with RSV at a newborn or weaning stage and were re-infected
5 weeks later. (Lee et al., 2008). Both WT and IFN-γ−/− mice
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developed similar levels of AHR and airway inﬂammation after
the primary infection (Lee et al., 2008). After re-infection, the
IFN-γ−/− mice, but not the WT mice, developed AHR, airway
eosinophilia, and mucus hyperproduction. The intranasal admin-
istration of IFN-γ during the primary infection, but not during
the re-infection, prevented the development of these altered airway
responses upon re-infection in the IFN-γ−/− mice. IFN-γproduc-
tion during primary RSV infection is critical to the development of
protection against AHR and airway eosinophilia as well as mucus
hyperproduction during subsequent re-infection (Lee et al., 2008).
To deﬁne the mechanism underlying the enhanced responsive-
ness in neonatally infected mice that were re-infected with RSV,
the differences between dendritic cells (DCs) from neonatal mice
and those from 5-week-old mice were examined. Neonatal lung
MHCII-positive (+) CD11b+ DCs expressed higher baseline lev-
els of OX40 ligand (OX40L) and lower cytoplasmic levels of IL-12
than lung DCs from 5-week-old mice (Han et al., 2012). Follow-
ing RSV infection, OX40L expression was increased in neonatal
DCs. The administration of anti-OX40L neutralizing antibody
during primary RSV infection in neonatal mice prevented the
subsequent enhancement of AHR and the development of airway
eosinophilia and mucus hyperproduction upon re-infection. The
basal expression levels of thymic stromal lymphopoietin (TSLP) in
the lungs were higher in the neonates than in the 5-week-old mice
(Han et al., 2012). RSV infection upregulates TSLP production in
epithelial cells (Han et al., 2012). The administration of anti-TSLP
neutralizing antibody before neonatal RSV infection reduced the
accumulation of lung DCs, decreased OX40L expression on lung
DCs, and attenuated the enhancement of the airway responses
after re-infection (Han et al., 2012).
Regulatory T (Treg) cells have an important role in immune
tolerance as early as the embryonic stage (Mold et al., 2008, 2010).
Treg cell-mediated protection from asthma is initiated at the
neonatal stage. Airborne antigens and ovalbumin (OVA) are efﬁ-
ciently transferred from mother mice to neonatal mice through
transforming growth factor (TGF)-β in lactated milk (Polte and
Hansen, 2008; Verhasselt et al., 2008). The repeated RSV infection
of infant mice impaired Treg cell function, leading to a mal-
function in tolerance to OVA contained in lactated milk. As a
result, RSV increased allergic airway inﬂammation in response
to OVA sensitization and subsequent challenges, compared with
inﬂammation in uninfected, tolerant control mice (Krishnamoor-
thy et al., 2012). Virus infection induced GATA-3 expression and
Th2 cytokine production in forkhead box P3 (FOXP3)+ Treg cells
and compromised the suppressive function of pulmonary Treg
cells. These ﬁndings highlight a mechanism by which viral infec-
tion targets a host-protective mechanism during early life and
increases susceptibility to allergic disease (Krishnamoorthy et al.
2012).
HUMORAL IMMUNITY OF VIRUS-INDUCED ASTHMA
Most children experience primary RSV infection when they are
infants. The immune system is still immature, and maternally
derived antibodies are still present at relatively high levels dur-
ing this period of life (Brandenburg et al., 1997). The titers of
maternally derived neutralizing antibodies are reportedly inversely
associated with RSV infection overall (Roca et al., 2002; Ochola
et al., 2009) andwith the severity of RSV illness (Glezen et al., 1981;
Holberg et al., 1991; Piedra et al., 2003; Stensballe et al., 2009). Pro-
phylaxis by Palivizumab, a humanized monoclonal anti-body that
targets the A antigenic site of the F-protein of RSV, substantially
reduces the risk of hospitalization in high-risk infants (Feltes et al.,
2003). However, maternally derived neutralizing antibodies have
a relatively weak ability to mount the antibody responses observed
in infants (Murphy et al., 1986). Signiﬁcant increases in serum
or nasal wash concentrations of RSV glycoprotein (G protein) or
fusion (F) protein-speciﬁc IgG and IgA are not seen in all infants
after primary RSV infection (Brandenburg et al., 1997; DeAlarcon
et al., 2001). The response of human neonatal B cells to RSV uses a
biased antibody variable gene repertoire that lacks somatic muta-
tions (Weitkamp et al., 2005; Williams et al., 2009). Because of
the poor Toll-like receptor stimulation in B cells, antibody afﬁn-
ity maturation is not sufﬁcient to elicit protection against RSV
re-infection (Delgado et al., 2009).
Palivizumab prophylaxis decreases the risk of hospitalization
in high-risk infants (Feltes et al., 2003) and the risk of recurrent
wheezing (Simoes et al., 2007). However, no effect of palivizumab
on subsequent recurrent wheezing was seen in children with a
family history of atopy or food allergies, compared with untreated
infants with an atopic family history (Simoes et al., 2010). This
ﬁnding suggests that RSV infection predisposes an individual to
recurrent wheezing in an atopy-independent manner and that
RSV infections of the lower respiratory tract may have differential
effects on the development of recurrent wheezing, depending on
the genetic predisposition.
Welliver et al. reported the presence of IgE antibodies recogniz-
ing whole RSV and puriﬁed F and G protein in a high proportion
of NPS samples from infants with RSV-induced bronchioli-
tis, but rarely in samples from infants with other RSV-induced
illnesses (Welliver et al., 1981, 1989). Although others have con-
ﬁrmed the presence of RSV-speciﬁc IgE serum and NPS from
some RSV-infected infants, such ﬁndings are generally seen in a
small proportion of patients (Bui et al., 1987; Russi et al., 1993;
Wilczynski et al., 1994; Rabatic et al., 1997; Aberle et al., 1999) or
not at all (De Alarcon et al., 2001).
In a mouse model, primary infection with RSV was capa-
ble of leading to the production of RSV-speciﬁc IgE, which may
contribute to the development of exaggerated Th2-based airway
responses upon reinfection in mice initially infected as neonates
(Dakhama et al., 2009).
RELATIONSHIP BETWEEN INNATE IMMUNE RESPONSE TO
INFECTION WITH RSV- AND/OR HRV-INDUCED ASTHMA
Wark et al. (2005) examined virus replication and innate responses
to RV-16 infection using primary bronchial epithelial cells from
asthmatic and healthy control subjects. Viral RNA expression and
late virus release into the supernatant was increased by 50- and
7-fold, respectively, in cells from asthmatic individuals, com-
pared with the levels in cells from healthy controls. The profound
impairment of virus-induced IFN-β production in cultures of
cells from asthmatic individuals was observed. In infected asth-
matic cells, exogenous IFN-β induced apoptosis and reduced virus
replication, demonstrating a causal link between deﬁcient IFN-β,
impaired apoptosis, and increased virus replication. Message
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et al. (2008) reported that HRV inoculation induced signiﬁcantly
greater lower respiratory symptoms and lung function impairment
and increases inAHR and eosinophilic lower airway inﬂammation
in asthmatic individuals, compared with normal volunteers. The
virologic and clinical outcomes were strongly related to deﬁcient
IFN-γ and IL-10 responses and to augmented IL-4, IL-5, and IL-13
responses. HRV was detected in the lower airway tissue of patients
with asthma signiﬁcantly more often than in non-asthmatic sub-
jects, and its presence was associated with the clinical features of
severer disease (Wos et al., 2008).
CONCLUSION
A prospective, repeated characterization of a birth cohort demon-
strated that sensitization to aeroallergens, beginning in the ﬁrst
year of life, consistently predisposes children to viral wheezing
illnesses and that the converse is not true (Jackson et al., 2013;
Figure 1). Some evidence suggests virus speciﬁcity, in that allergic
sensitization speciﬁcally increased the risk of wheezing in indi-
viduals with HRV infections, but not those with RSV infections.
This sequential relationship and the plausible mechanisms by
which allergic sensitization can lead to severerHRV-induced lower
respiratory illnesses support a causal role for allergic sensitization
in this developmental pathway (Jackson et al., 2013). Subrata et al.
(2009) suggested that interactions between innate antiviral and
allergic inﬂammatory pathways may lead to severer viral illnesses
in atopic children. Ongoing allergic inﬂammation in the airways
may directly lead to impairment of the epithelial cell barrier and
the antiviral response (Figure 1). Accordingly, respiratory viral
infection in atopic children may initiate an atopy-dependent cas-
cade that ampliﬁes and sustains airway inﬂammation initiated by
innate antiviral immunity via harnessing the underlying atopy-
associated mechanisms (Subrata et al., 2009). Allergic asthmatic
children had higher surface expression of FcεRIα on plasmacytoid
(p) DCs and myeloid (m) DCs when compared with that seen in
nonallergic, nonasthmatic children. The percentage of FcεRIα+
pDCs and mDCs in allergic asthmatic children was inversely cor-
related with HRV-induced IFN-α and IFN-λ1, and IFN-α produc-
tion levels, respectively (Figure 1). Following aggregation of FcεRI,
HRV-induced IFN-α and IFN-λ1 production from peripheral
blood mononuclear cells (PBMCs) was signiﬁcantly reduced
FIGURE 1 | Possible immunological mechanisms of HRV-induced
bronchial asthma in infants. Sensitization to aeroallergens, beginning in the
ﬁrst year of life, consistently predisposes children to HRV-induced wheezing
illnesses. Ongoing allergic inﬂammation in the airways may directly lead to
impairment of the epithelial cell barrier and antiviral response. Following
aggregation of FcεRI, HRV-induced IFN-α and IFN-λ1 production from PBMCs
and DCs is signiﬁcantly reduced compared to that by HRV stimulation alone.
Furthermore, impairment of virus-induced IFNs from epithelial cells due to
genetic variants increases virus replication. HRV infection upregulates TSLP
production in epithelial cells (Kato et al., 2007). Neonatal lung DCs express
higher baseline levels of OX40 ligand (OX40L) and lower cytoplasmic levels of
IL-12 than lung DCs from adult lung DCs. TSLP upregulates the expression of
OX40L on DCs. Airway inﬂammation and AHR may be enhanced after
re-infection
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compared to that by HRV stimulation alone (Durrani et al., 2012).
These effects may explain why children with allergic asthma have
more frequent and severe HRV-induced wheezing and asthma
exacerbations. In contrast, the administration of palivizumab
prophylaxis had no effect on subsequent recurrent wheezing in
children with a family history of atopy (Simoes et al., 2010).
This ﬁnding suggests that RSV infection predisposes individuals
to recurrent wheezing through an atopy-independent mecha-
nism. Several asthmatic or wheezing phenotypes exist in children
(Fitzpatrick et al., 2011). Therefore, respiratory virus-induced
wheezing illnesses can encompass multiple sub-phenotypes that
relate to asthma in different ways.
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